Evidence map›Paper›PMID 36866159›Full record

ReviewThe EPMA journal2023

New insight of metabolomics in ocular diseases in the context of 3P medicine.

Quyan Zhang, Nan Wang, Yuhua Rui, Yang Xia, Siqi Xiong, Xiaobo Xia

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The EPMA journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
8.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 31 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Quyan ZhangEye Center of Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, 410008 Hunan Province China.
Nan WangEye Center of Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, 410008 Hunan Province China.
Yuhua RuiEye Center of Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, 410008 Hunan Province China.
Yang XiaNational Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, 410008 China.
Siqi XiongEye Center of Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, 410008 Hunan Province China.
Xiaobo XiaEye Center of Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, 410008 Hunan Province China.ORCID 0000-0003-1720-7860
Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metabolomics refers to the high-through untargeted or targeted screening of metabolites in biofluids, cells, and tissues. Metabolome reflects the functional states of cells and organs of an individual, influenced by genes, RNA, proteins, and environment. Metabolomic analyses help to understand the interaction between metabolism and phenotype and reveal biomarkers for diseases. Advanced ocular diseases can lead to vision loss and blindness, reducing patients' quality of life and aggravating socio-economic burden. Contextually, the transition from reactive medicine to the predictive, preventive, and personalized (PPPM / 3P) medicine is needed. Clinicians and researchers dedicate a lot of efforts to explore effective ways for disease prevention, biomarkers for disease prediction, and personalized treatments, by taking advantages of metabolomics. In this way, metabolomics has great clinical utility in the primary and secondary care. In this review, we summarized much progress achieved by applying metabolomics to ocular diseases and pointed out potential biomarkers and metabolic pathways involved to promote 3P medicine approach in healthcare.

Indexed as

Age-related macular degenerationBiomarkersDiabetic retinopathyGlaucomaMetabolomicsOcular diseasesPredictive preventive personalized medicine (3PM / PPPM)

Identifiers

PMID36866159
PMCPMC9971428
OpenAlexW4321250381

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.